MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
39.05
-4.07
-9.44%
After Hours: 39.05 0 0.00% 19:54 06/14 EDT
OPEN
40.93
PREV CLOSE
43.12
HIGH
41.00
LOW
38.16
VOLUME
4.11M
TURNOVER
0
52 WEEK HIGH
54.56
52 WEEK LOW
31.52
MARKET CAP
3.25B
P/E (TTM)
-4.8667
1D
5D
1M
3M
1Y
5Y
RPT-BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Hasbro, VinFast
U.S. Stock indexes fall on Friday. Nasdaq and S&P 500 slip from record highs. Investors booked profits and weighed hawkish Fed projections against slowing economic data. The Dow Jones Industrial Average was down 0.27% and the Nasdaq Composite was up 0.11%.
Reuters · 1d ago
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session. AMMO reported a fourth-quarter profit of 1 cent per share. The company reported quarterly sales of $40.42 million. Kaival Brands Innovations Group, Inc (KAVL) shares jumped 345% to $6.06.
Benzinga · 1d ago
BUZZ-Ultragenyx Pharma falls on stock offering pricing
Shares of Ultragenyx Pharmaceutical RARE.O shares down 4.9% at $41 before the bell after co secures equity raise. Rare disease drug developer announced pricing of 9 million shares at $39 for $350 million. Co to use proceeds to advance late-stage clinical programs.
Reuters · 1d ago
Health Care Sector Update for 06/14/2024: CABA, VXRT, RARE, XLV, IBB
NASDAQ · 1d ago
ULTRAGENYX PHARMACEUTICAL SHARES DOWN 2.8% PREMARKET AFTER CO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Reuters · 2d ago
Ultragenyx Pharmaceutical prices $350 million securities offering
Ultragenyx Pharmaceutical Inc. Prices $350 million securities offering. The offering is expected to close on June 17, 2024. The company expects gross proceeds from the offering to be in excess of $300 million. Ultragenyx is a biopharmaceutical company.
Seeking Alpha · 2d ago
Ultragenyx Pharma Prices Public Offering Of About 7.44 Mln Shares At $39.00/shr
NASDAQ · 2d ago
*Ultragenyx Prices Public Offering of Stock, Prefunded Warrants >RARE
Dow Jones · 2d ago
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.